IGF1R and ovarian carcinoma: A phase I/II clinical trial has started recently for patients with ovarian cancer or breast cancer to evaluate the therapeutic benefit of combining BYL719 with the anti-IGF1R antibody AMG479 (ClinicalTrials.gov NCT01708161).